Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vertex Pharmaceuticals (NQ: VRTX )

495.42 +7.08 (+1.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
58 59 Next >
Vertex to Present Data Highlighting Long-Term Benefits of TRIKAFTA® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?
This stock could be a long-term winner, thanks to its game-changing technology. 
Via The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Via Benzinga
Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug
The agency could soon approve a potential cure for sickle cell disease . 
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Exploring NASDAQ:VRTX's quality characteristics.
Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors. 
Via Chartmill
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
Via Benzinga
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade
4x returns in just a decade is quite an attainable result for these companies. 
Via The Motley Fool
CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy
Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock. 
Via InvestorPlace
Exposures Product Safety
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next  
Via Benzinga
Exposures Product Safety
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money
These companies come from very different industries, but each has businesses that investors may find compelling. 
Via The Motley Fool
IBD's 100 Best ESG Companies For 2023
The companies on our list combine high sustainability scores and top stock ratings. 
Via Investor's Business Daily
2 Healthcare Stocks That Could Make You Richer
The need for healthcare is consistent and ongoing, a reality that makes this industry resilient to economic downturns. 
Via The Motley Fool
2 Top Healthcare Stocks Defying the Bear Market
These companies are building out their revenue and profit streams, and the proof is in the pudding. 
Via The Motley Fool
This Market-Beating Growth Stock Is Set to Outperform Yet Again in 2024
This rare disease company is on a roll. 
Via The Motley Fool
2 Best Healthcare Stocks to Buy Right Now
The healthcare industry is an explosive space full of promising, profitable companies. 
Via The Motley Fool
Vertex to Present at Upcoming Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals: Buy at the High?
Vertex shares have been flying high in recent times. 
Via The Motley Fool
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Great healthcare businesses are out there and their stocks are ripe for the picking. 
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy Right Now
These businesses are thriving and raking in profits. 
Via The Motley Fool
2 Fantastic Growth Stocks to Buy Hand Over Fist
These stocks make great bargains today. 
Via The Motley Fool
3 Red-Hot Growth Stocks That Are Still Cheap Buys
It's not too late to invest in these great businesses. 
Via The Motley Fool
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
The Best Stocks to Invest $5,000 In Right Now
Today, the following three healthcare players look like fantastic bargains. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Sooner Rather Than Later
Now is the time to invest in these great stocks. 
Via The Motley Fool
3 Monster Stocks to Buy Without Any Hesitation
These big stocks could become a lot bigger. 
Via The Motley Fool
4 Ways to Grow $100,000 Into $1 Million for Retirement
Investing for big-time growth doesn't have to be risky. 
Via The Motley Fool
Vertex Pharmaceuticals, Gilead Sciences And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed lower by over 200 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.